Portfolio Holdings Detail for ISIN IE00BFF5RZ82
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Edge MSCI USA Momentum Factor UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker IUMD(USD) LSE
ETF Ticker IUMD.L(GBP) LSE

Holdings detail for ALNY

Stock Name	Alnylam Pharmaceuticals Inc
Ticker	ALNY(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US02043Q1076
LEI	529900S3ZI14OWRJII50

Show aggregate ALNY holdings

News associated with ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by Royal Bank Of Canada from $435.00 to $500.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ALNY has been the topic of several other reports. The Goldman Sachs Group boosted their price […] - 2025-09-22 02:32:43
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $520.00 Price Target at Bank of America: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective raised by Bank of America from $453.00 to $520.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on ALNY. Oppenheimer upgraded shares […] - 2025-09-18 04:26:54
The Goldman Sachs Group Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by The Goldman Sachs Group from $504.00 to $566.00 in a report published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on the stock. Chardan Capital lifted […] - 2025-09-17 03:14:44
Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $421.28: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-seven analysts that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 1 year target price […] - 2025-09-15 02:47:58
Alnylam Announces Pricing Of Upsized Offering Of $575 Mln Convertible Senior Notes Due 2028: (RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced the pricing of its private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028. The size of the offering was increased from the previously announced offering of $500 million aggre - 2025-09-10 00:33:28
Alnylam Pharma Commences Private Offering Of $500 Mln Of Convertible Senior Notes Due 2028: (RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028. In connection with this offering, Alnylam expects to grant the initial purchasers of the notes an op - 2025-09-09 00:30:30
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win: Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study. - 2025-09-01 11:50:00
Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
Dennis A. Ausiello Sells 31,448 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares in […] - 2025-08-18 05:14:55
LPL Financial LLC Buys 2,107 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): LPL Financial LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 11.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,679 shares of the biopharmaceutical company’s stock after acquiring an additional 2,107 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-13 05:04:56
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Cetera Investment Advisers Has $2.17 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Cetera Investment Advisers raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 68.1% during the first quarter, Holdings Channel reports. The firm owned 8,017 shares of the biopharmaceutical company’s stock after purchasing an additional 3,247 shares during the period. Cetera Investment Advisers’ holdings in Alnylam Pharmaceuticals were worth $2,165,000 at the end […] - 2025-08-08 04:44:59
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Oppenheimer: Oppenheimer upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage currently has $490.00 target price on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. Barclays lifted their price […] - 2025-08-07 02:54:47
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by Wolfe Research to Peer Perform Rating: Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities research analysts at Wolfe Research from an “underperform” rating to a “peer perform” rating in a research report issued on Monday, Marketbeat reports. A number of other brokerages have also recently issued reports on ALNY. Canaccord Genuity Group lifted their price target on shares […] - 2025-08-06 03:02:54
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $400.00 at Chardan Capital: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Chardan Capital from $325.00 to $400.00 in a research report report published on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on ALNY. Needham & Company LLC raised their […] - 2025-08-04 02:48:47
Needham & Company LLC Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $478.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target hoisted by Needham & Company LLC from $377.00 to $478.00 in a research report report published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts also recently commented on the […] - 2025-08-03 05:28:56
Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03
Y Intercept Hong Kong Ltd Has $1 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Y Intercept Hong Kong Ltd lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 17.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,720 shares of the biopharmaceutical company’s stock after selling 796 shares during the period. […] - 2025-07-25 06:12:53
Victory Capital Management Inc. Cuts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Victory Capital Management Inc. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,649 shares of the biopharmaceutical company’s stock after selling 2,148 shares during the period. Victory Capital […] - 2025-07-25 05:14:50
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twenty-six research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twenty-two have assigned a buy recommendation to the […] - 2025-07-24 06:26:55
Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Truist Financial: Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $385.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts also recently issued reports on ALNY. Jefferies Financial […] - 2025-07-22 03:14:59
Nisa Investment Advisors LLC Cuts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Nisa Investment Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 38.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,155 shares of the biopharmaceutical company’s stock after selling 5,162 shares during […] - 2025-07-14 05:54:56
Crossmark Global Holdings Inc. Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Crossmark Global Holdings Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,018 shares of the biopharmaceutical company’s stock, valued at approximately $275,000. Other hedge funds have also modified their holdings of the […] - 2025-07-14 05:14:48
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Vontobel Holding Ltd.: Vontobel Holding Ltd. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,691 shares of the biopharmaceutical company’s stock after selling 113 shares during the […] - 2025-07-08 04:40:51
Mirae Asset Global Investments Co. Ltd. Sells 2,596 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 28.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,534 shares of the biopharmaceutical company’s stock after selling 2,596 shares during the […] - 2025-07-04 04:52:27
Wells Fargo & Company Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $333.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target lifted by research analysts at Wells Fargo & Company from $287.00 to $333.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside […] - 2025-07-02 03:05:01
Diversified Trust Co Sells 999 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Diversified Trust Co cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 40.3% in the first quarter, Holdings Channel reports. The institutional investor owned 1,482 shares of the biopharmaceutical company’s stock after selling 999 shares during the period. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $400,000 as of […] - 2025-07-01 07:10:56
Sequoia Financial Advisors LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Sequoia Financial Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.0% in the first quarter, HoldingsChannel reports. The fund owned 3,395 shares of the biopharmaceutical company’s stock after acquiring an additional 99 shares during the period. Sequoia Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $917,000 […] - 2025-07-01 05:22:50
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High Following Analyst Upgrade: Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) hit a new 52-week high on Monday after Wells Fargo & Company raised their price target on the stock from $287.00 to $333.00. Wells Fargo & Company currently has an equal weight rating on the stock. Alnylam Pharmaceuticals traded as high as $327.05 and last […] - 2025-07-01 02:27:01
Kentucky Retirement Systems Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Kentucky Retirement Systems bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,794 shares of the biopharmaceutical company’s stock, valued at approximately $2,375,000. Several other institutional investors and […] - 2025-06-24 06:20:52

iShares Edge MSCI USA Momentum Factor UCITS ETF USD (Dist) ALNY holdings

Date	Number of ALNY Shares Held	Base Market Value of ALNY Shares	Local Market Value of ALNY Shares	Change in ALNY Shares Held	Change in ALNY Base Value	Current Price per ALNY Share Held	Previous Price per ALNY Share Held
2025-09-18 (Thursday)	6,176	USD 2,792,602	USD 2,792,602	0	USD 2,748	USD 452.17	USD 451.725
2025-09-17 (Wednesday)	6,176	USD 2,789,854	USD 2,789,854	0	USD -58,764	USD 451.725	USD 461.24
2025-09-16 (Tuesday)	6,176	USD 2,848,618	USD 2,848,618	0	USD 617	USD 461.24	USD 461.14
2025-09-15 (Monday)	6,176	USD 2,848,001	USD 2,848,001
2025-09-12 (Friday)	6,261	USD 2,916,937	USD 2,916,937	85	USD 22,987	USD 465.89	USD 468.58
2025-09-11 (Thursday)	6,176	USD 2,893,950	USD 2,893,950	-85	USD -44,400	USD 468.58	USD 469.31
2025-09-10 (Wednesday)	6,261	USD 2,938,350	USD 2,938,350	0	USD -80,266	USD 469.31	USD 482.13
2025-09-09 (Tuesday)	6,261	USD 3,018,616	USD 3,018,616	0	USD 169,673	USD 482.13	USD 455.03

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ALNY by Blackrock for IE00BFF5RZ82

Show aggregate share trades of ALNY

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-09-12 BUY 85 465.890* 280.63
2025-09-11 SELL -85 468.580* 279.62 Profit of 23,767 on sale
2025-07-31 BUY 64 392.240* 274.94
2025-07-30 SELL -64 339.800* 274.58 Profit of 17,573 on sale
2025-07-25 SELL -64 328.810* 273.67 Profit of 17,515 on sale
2025-07-24 BUY 128 328.000* 273.36
2025-07-14 SELL -64 315.750* 272.00 Profit of 17,408 on sale
2025-07-11 SELL -256 314.940* 271.75 Profit of 69,567 on sale
2025-07-10 BUY 384 322.640* 271.45
2025-07-07 SELL -252 324.130* 270.55 Profit of 68,180 on sale
2025-07-03 SELL -63 331.910* 269.81 Profit of 16,998 on sale
2025-06-30 SELL -252 326.090* 269.09 Profit of 67,810 on sale
2025-06-27 BUY 504 322.830* 268.75
2025-06-24 SELL -189 325.000* 267.75 Profit of 50,604 on sale
2025-06-23 SELL -63 313.130* 267.46 Profit of 16,850 on sale
2025-06-20 SELL -189 309.700* 267.19 Profit of 50,499 on sale
2025-06-18 SELL -248 312.320* 266.60 Profit of 66,117 on sale
2025-06-17 BUY 372 308.710* 266.33
2025-06-13 BUY 124 307.990* 265.77
2025-06-12 SELL -620 304.670* 265.51 Profit of 164,617 on sale
2025-06-11 BUY 124 298.580* 265.29
2025-06-05 SELL -62 308.000* 264.23 Profit of 16,382 on sale
2025-06-04 BUY 62 305.310* 263.94
2025-05-30 SELL -1,740 304.560* 263.07 Profit of 457,744 on sale
2025-05-29 SELL -88 292.900* 262.86 Profit of 23,132 on sale
2025-05-23 SELL -176 289.960* 262.09 Profit of 46,128 on sale
2025-05-22 SELL -176 289.000* 261.89 Profit of 46,093 on sale
2025-05-20 BUY 88 291.680* 261.44
2025-05-19 BUY 176 291.860* 261.21
2025-05-16 BUY 264 285.310* 261.02
2025-05-15 BUY 88 283.400* 260.85
2025-05-12 BUY 352 270.190* 260.68
2025-05-07 BUY 88 276.550* 260.65
2025-04-25 SELL -87 251.560* 260.65 Profit of 22,677 on sale
2025-04-23 BUY 87 241.970* 260.97
2025-04-22 BUY 87 236.750* 261.19
2025-04-15 SELL -261 230.930* 262.51 Profit of 68,514 on sale
2025-04-10 SELL -261 226.280* 263.30 Profit of 68,722 on sale
2025-04-07 SELL -87 232.950* 264.18 Profit of 22,983 on sale
2025-04-02 SELL -87 266.830* 264.44 Profit of 23,006 on sale
2025-04-01 BUY 87 255.760* 264.52
2025-03-31 SELL -174 270.020* 264.47 Profit of 46,017 on sale
2025-03-28 SELL -87 268.460* 264.43 Profit of 23,005 on sale
2025-03-25 SELL -88 280.960* 264.13 Profit of 23,243 on sale
2025-03-21 BUY 174 283.340* 263.63
2025-03-19 BUY 87 253.440* 263.86
2025-03-18 SELL -87 244.300* 264.08 Profit of 22,975 on sale
2025-03-17 BUY 174 253.110* 264.20
2025-03-13 SELL -87 241.750* 264.72 Profit of 23,031 on sale
2025-03-07 BUY 87 244.520* 265.94
2025-03-05 BUY 261 249.230* 266.15
2025-02-26 BUY 95 243.860* 267.68
2025-02-25 SELL -87 245.200* 267.98 Profit of 23,315 on sale
2025-02-21 SELL -87 250.590* 268.48 Profit of 23,358 on sale
2025-02-12 BUY 88 265.960* 269.76
2025-02-06 BUY 88 278.250* 269.46
2025-01-31 SELL -88 271.310* 269.20 Profit of 23,689 on sale
2025-01-29 SELL -88 273.990* 268.97 Profit of 23,669 on sale
2025-01-28 SELL -176 279.190* 268.78 Profit of 47,306 on sale
2025-01-24 BUY 264 278.760* 268.44
2025-01-23 SELL -176 275.540* 268.31 Profit of 47,222 on sale
2025-01-02 SELL -88 233.620* 268.99 Profit of 23,671 on sale
2024-12-09 SELL -88 255.890* 269.56 Profit of 23,722 on sale
2024-12-06 BUY 174 256.260* 269.84
2024-11-25 SELL -1,127 250.980* 274.91 Profit of 309,825 on sale
2024-11-25 SELL -1,127 250.980* 274.91 Profit of 309,825 on sale
2024-11-22 BUY 103 244.890* 275.75
2024-11-20 BUY 103 248.790* 277.39
2024-11-18 BUY 206 232.270* 280.15
2024-11-12 BUY 408 268.950* 280.89
2024-11-12 BUY 408 268.950* 280.89
2024-11-07 BUY 102 272.220* 281.83
2024-11-07 BUY 102 272.220* 281.83
2024-11-04 SELL -309 269.950* 285.55 Profit of 88,235 on sale
2024-11-04 SELL -309 269.950* 285.55 Profit of 88,235 on sale
2024-10-30 BUY 103 281.490* 290.50
2024-10-30 BUY 103 281.490* 290.50
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-09-12	BUY	85	465.890*	280.63
2025-09-11	SELL	-85	468.580*	279.62 Profit of 23,767 on sale
2025-07-31	BUY	64	392.240*	274.94
2025-07-30	SELL	-64	339.800*	274.58 Profit of 17,573 on sale
2025-07-25	SELL	-64	328.810*	273.67 Profit of 17,515 on sale
2025-07-24	BUY	128	328.000*	273.36
2025-07-14	SELL	-64	315.750*	272.00 Profit of 17,408 on sale
2025-07-11	SELL	-256	314.940*	271.75 Profit of 69,567 on sale
2025-07-10	BUY	384	322.640*	271.45
2025-07-07	SELL	-252	324.130*	270.55 Profit of 68,180 on sale
2025-07-03	SELL	-63	331.910*	269.81 Profit of 16,998 on sale
2025-06-30	SELL	-252	326.090*	269.09 Profit of 67,810 on sale
2025-06-27	BUY	504	322.830*	268.75
2025-06-24	SELL	-189	325.000*	267.75 Profit of 50,604 on sale
2025-06-23	SELL	-63	313.130*	267.46 Profit of 16,850 on sale
2025-06-20	SELL	-189	309.700*	267.19 Profit of 50,499 on sale
2025-06-18	SELL	-248	312.320*	266.60 Profit of 66,117 on sale
2025-06-17	BUY	372	308.710*	266.33
2025-06-13	BUY	124	307.990*	265.77
2025-06-12	SELL	-620	304.670*	265.51 Profit of 164,617 on sale
2025-06-11	BUY	124	298.580*	265.29
2025-06-05	SELL	-62	308.000*	264.23 Profit of 16,382 on sale
2025-06-04	BUY	62	305.310*	263.94
2025-05-30	SELL	-1,740	304.560*	263.07 Profit of 457,744 on sale
2025-05-29	SELL	-88	292.900*	262.86 Profit of 23,132 on sale
2025-05-23	SELL	-176	289.960*	262.09 Profit of 46,128 on sale
2025-05-22	SELL	-176	289.000*	261.89 Profit of 46,093 on sale
2025-05-20	BUY	88	291.680*	261.44
2025-05-19	BUY	176	291.860*	261.21
2025-05-16	BUY	264	285.310*	261.02
2025-05-15	BUY	88	283.400*	260.85
2025-05-12	BUY	352	270.190*	260.68
2025-05-07	BUY	88	276.550*	260.65
2025-04-25	SELL	-87	251.560*	260.65 Profit of 22,677 on sale
2025-04-23	BUY	87	241.970*	260.97
2025-04-22	BUY	87	236.750*	261.19
2025-04-15	SELL	-261	230.930*	262.51 Profit of 68,514 on sale
2025-04-10	SELL	-261	226.280*	263.30 Profit of 68,722 on sale
2025-04-07	SELL	-87	232.950*	264.18 Profit of 22,983 on sale
2025-04-02	SELL	-87	266.830*	264.44 Profit of 23,006 on sale
2025-04-01	BUY	87	255.760*	264.52
2025-03-31	SELL	-174	270.020*	264.47 Profit of 46,017 on sale
2025-03-28	SELL	-87	268.460*	264.43 Profit of 23,005 on sale
2025-03-25	SELL	-88	280.960*	264.13 Profit of 23,243 on sale
2025-03-21	BUY	174	283.340*	263.63
2025-03-19	BUY	87	253.440*	263.86
2025-03-18	SELL	-87	244.300*	264.08 Profit of 22,975 on sale
2025-03-17	BUY	174	253.110*	264.20
2025-03-13	SELL	-87	241.750*	264.72 Profit of 23,031 on sale
2025-03-07	BUY	87	244.520*	265.94
2025-03-05	BUY	261	249.230*	266.15
2025-02-26	BUY	95	243.860*	267.68
2025-02-25	SELL	-87	245.200*	267.98 Profit of 23,315 on sale
2025-02-21	SELL	-87	250.590*	268.48 Profit of 23,358 on sale
2025-02-12	BUY	88	265.960*	269.76
2025-02-06	BUY	88	278.250*	269.46
2025-01-31	SELL	-88	271.310*	269.20 Profit of 23,689 on sale
2025-01-29	SELL	-88	273.990*	268.97 Profit of 23,669 on sale
2025-01-28	SELL	-176	279.190*	268.78 Profit of 47,306 on sale
2025-01-24	BUY	264	278.760*	268.44
2025-01-23	SELL	-176	275.540*	268.31 Profit of 47,222 on sale
2025-01-02	SELL	-88	233.620*	268.99 Profit of 23,671 on sale
2024-12-09	SELL	-88	255.890*	269.56 Profit of 23,722 on sale
2024-12-06	BUY	174	256.260*	269.84
2024-11-25	SELL	-1,127	250.980*	274.91 Profit of 309,825 on sale
2024-11-25	SELL	-1,127	250.980*	274.91 Profit of 309,825 on sale
2024-11-22	BUY	103	244.890*	275.75
2024-11-20	BUY	103	248.790*	277.39
2024-11-18	BUY	206	232.270*	280.15
2024-11-12	BUY	408	268.950*	280.89
2024-11-12	BUY	408	268.950*	280.89
2024-11-07	BUY	102	272.220*	281.83
2024-11-07	BUY	102	272.220*	281.83
2024-11-04	SELL	-309	269.950*	285.55 Profit of 88,235 on sale
2024-11-04	SELL	-309	269.950*	285.55 Profit of 88,235 on sale
2024-10-30	BUY	103	281.490*	290.50
2024-10-30	BUY	103	281.490*	290.50

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ALNY

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	216,727	3,259	396,243	54.7%
2025-09-18	172,875	397	386,432	44.7%
2025-09-17	246,547	167	472,292	52.2%
2025-09-16	88,846	60	226,336	39.3%
2025-09-15	148,258	13,572	435,689	34.0%
2025-09-12	134,122	300	244,968	54.8%
2025-09-11	219,868	7,820	411,702	53.4%
2025-09-10	543,326	7,595	916,898	59.3%
2025-09-09	705,540	33,731	1,550,899	45.5%
2025-09-08	175,158	440	388,715	45.1%
2025-09-05	127,116	335	311,252	40.8%
2025-09-04	110,930	2,555	236,568	46.9%
2025-09-03	182,386	8,982	562,921	32.4%
2025-09-02	132,770	14,416	358,476	37.0%
2025-08-29	93,216	2,181	276,594	33.7%
2025-08-28	60,182	1,254	226,865	26.5%
2025-08-27	277,667	1,084	440,577	63.0%
2025-08-26	243,404	919	447,421	54.4%
2025-08-25	156,551	15,662	374,276	41.8%
2025-08-22	228,596	1,309	408,152	56.0%
2025-08-21	123,996	2,862	248,300	49.9%
2025-08-20	149,638	13,723	316,983	47.2%
2025-08-19	144,320	1,143	308,399	46.8%
2025-08-18	371,318	34,264	525,786	70.6%
2025-08-15	104,018	13,245	265,620	39.2%
2025-08-14	133,272	4,443	505,528	26.4%
2025-08-13	183,271	1,390	1,017,623	18.0%
2025-08-12	173,045	4,046	693,018	25.0%
2025-08-11	239,199	7,600	451,248	53.0%
2025-08-08	168,755	3,199	466,744	36.2%
2025-08-07	308,810	4,452	527,399	58.6%
2025-08-06	202,151	12,590	548,349	36.9%
2025-08-05	256,295	13,237	826,283	31.0%
2025-08-04	411,114	36,303	729,949	56.3%
2025-08-01	350,060	60,108	764,943	45.8%
2025-07-31	829,191	6,023	1,541,015	53.8%
2025-07-30	533,885	14,703	942,788	56.6%
2025-07-29	164,268	55	384,537	42.7%
2025-07-28	150,240	69	571,965	26.3%
2025-07-25	90,782	429	298,801	30.4%
2025-07-24	132,001	11,546	286,155	46.1%
2025-07-23	184,149	63	312,340	59.0%
2025-07-22	134,761	7,553	524,612	25.7%
2025-07-21	113,303	101	243,119	46.6%
2025-07-18	84,117	9	196,317	42.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Edge MSCI USA Momentum Factor UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	IUMD(USD) LSE
ETF Ticker	IUMD.L(GBP) LSE